{"version":"1.0","type":"link","title":"Post-marketing surveillance of quizartinib for relapsed or refractory FLT3-ITD-positive acute myeloid leukemia in Japan.","author_name":"Miyazaki Y 외","author_url":"https://prs-insight.online/author/Miyazaki%20Y","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/161321","thumbnail_width":1200,"thumbnail_height":630}